These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 5668416)

  • 21. [Clinical effects of L-dopa in Parkinson's disease].
    Fasano VA
    Sist Nerv; 1970; 22(2):119-23. PubMed ID: 5504550
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of Levo-Dopa in the treatment of Parkinsonism (188 cases)].
    Fasano VA; Urciuoli R; Broggi G; Lombard GF
    Minerva Neurochir; 1970; 14(2):245-9. PubMed ID: 5515308
    [No Abstract]   [Full Text] [Related]  

  • 23. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 24. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 25. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    Sharma JC
    Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
    [No Abstract]   [Full Text] [Related]  

  • 26. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

  • 27. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 28. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Parkinson's syndrome. 11. Intestinal resorption].
    Jagenburg R
    Lakartidningen; 1970 Oct; 67(42):4842-4. PubMed ID: 5483445
    [No Abstract]   [Full Text] [Related]  

  • 31. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parkinson's syndrome. 10. Effects of psychopharmacological agents on central monoamine neurons].
    Roos BE
    Lakartidningen; 1970 Oct; 67(42):4840-1. PubMed ID: 4320249
    [No Abstract]   [Full Text] [Related]  

  • 34. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Aasly J; Sjaastad O; Rinne U; McIntyre T; Cremer G
    Adv Neurol; 1993; 60():676-80. PubMed ID: 8420209
    [No Abstract]   [Full Text] [Related]  

  • 35. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 36. [Parkinson's disease].
    Mizuno Y
    No To Shinkei; 1994 Mar; 46(3):217-27. PubMed ID: 7910751
    [No Abstract]   [Full Text] [Related]  

  • 37. L-dopa--MAO inhibitors.
    Del Med J; 1971 Aug; 43(8):236. PubMed ID: 5094611
    [No Abstract]   [Full Text] [Related]  

  • 38. Rasagiline (Azilect) for Parkinson's disease.
    Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358
    [No Abstract]   [Full Text] [Related]  

  • 39. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.